1. Contractors
  2. Elusys Therapeutics Inc

Elusys Therapeutics Inc

Federal contractor · Pharmaceutical Preparation Manufacturing

Elusys Therapeutics has 3 federal contracts of $100,000 or more active since October 2023, with $343M obligated, from 1 agency. 1 is still running.

Contracts
3 since FY2024$342,728,525 obligated, contracts of $100,000 or more
Running now
1 contract
Biggest customer
Office of Assistant Secretary for Preparedness and Response$343M on 3 contracts
UEI
ELP1DCK8L191Unique entity ID in SAM.gov
Source
USAspending.govUpdated Nov 17, 2026, 7:02 PM UTC

Contracts by start year

Obligated so far on contracts active since October 2023, by the fiscal year each started. Fiscal years run Oct 1 to Sep 30.
Show as table
Fiscal yearContracts
FY2021$79,947,200
FY2024$124,523,123

Running contracts

Soonest end first. An agency may compete the work again, extend the contract or move it to another vehicle.

ContractObligatedEndsState
Anthim (Obiltoxaximab)Office of Assistant Secretary for Preparedness and Response · 75A50324C00006$124,523,123Dec 31, 2028in 25 monthsNJ

End dates are the current period of performance; options not yet exercised can extend them. Each contract links to its record on USAspending.gov.

Who they work for

AgencyAmount, $M
Office of Assistant Secretary for Preparedness and Response3 contracts342.7

What they sell

IndustryAmount, $M
Pharmaceutical Preparation ManufacturingNAICS 325412 · 2 contracts204.5
Research and Development in BiotechnologyNAICS 541711 · 1 contract138.3

Where the work is

Place of workAmount, $M
New Jersey3 contracts342.7

Source: USAspending.gov, prime contracts of $100,000 or more with an action since October 1, 2023. Department of Defense contracts appear there about 90 days after award. Other contracts ending soon at Office of Assistant Secretary for Preparedness and Response: see the list.

Get new notices like Elusys Therapeutics's work

New contract opportunities under NAICS 325412, pharmaceutical preparation manufacturing, the morning they appear. Free while in beta.

Free. We use your email only for these alerts and never share it. Privacy